强志散治疗多发性抽动症临床疗效观察及实验研究

发布时间：2018-05-02 08:36

本文选题：强志散 + 多发性抽动症　；参考：《山东中医药大学》2016年硕士论文

【摘要】：目的:通过强志散治疗多发性抽动症(肾志不足型)患儿在抽动类型、频度、强度以及对行为影响程度方面与西药硫必利观察比较,客观评价强志散的有效性,并结合动物实验,初步探究强志散对脑组织DA、NE的干预机制,为志意辨证理论修复完善提供参考。方法:1.临床部分:将符合纳入标准的60例患儿随机分为强志散组和硫必利组,每组30例,强志组口服强志散汤剂,硫必利组口服硫必利。治疗24周,随访24周。观察两组治疗前后总疗效、运动性抽动、发声性抽动以及抽动的类型、频率、强度、复杂程度、对生活干扰程度的疗效、不良反应、安全性和远期疗效。2.实验部分:40只SD大鼠随机分为对照组、模型组、硫必利组、强志散组,每组10只。通过腹腔注射IDPN,300mg/kg,1次/d,连续7d,建立TS大鼠模型。强志散组按照5g/kg剂量灌服免煎颗粒,硫比利组按照25mg/kg剂量灌服硫必利,其余二组同时灌服等剂量生理盐水。连续灌服4周。观察大鼠体重及运动行为变化并检测脑组织DA、NE含量。结果:1.临床部分:在改善总体抽动、运动抽动、抽动频率、抽动强度、对生活干扰程度方面,强志散疗效优于硫必利(p0.05)。在改善发声抽动、抽动类型、复杂程度方面,强志散与硫必利疗效相当(p0.05)。在中医临床症候改善方面,强志散明显优于硫必利(p0.01)。2.实验部分:强志散组大鼠脑组织DA、NE含量较硫必利组明显降低(p0.05)。结论:强志散临床治疗多发性抽动症(肾志不足型)安全有效,降低大鼠脑内DA、NE含量可能是强志散治疗抽动症的作用机制之一。
[Abstract]:Objective: to evaluate the effectiveness of Qiangzhi Powder in treating children with multiple tic syndrome (deficiency of renal history) in terms of twitch type, frequency, intensity and the degree of influence on behavior, and to evaluate the effectiveness of Qiangzhi San objectively compared with that of western medicine tiapride. Combined with animal experiments, the intervention mechanism of Qiangzhi San on brain tissue DANNE was preliminarily explored, which provided a reference for the improvement of the theory of Yiyi differentiation of symptoms and signs. Method 1: 1. Clinical part: 60 children who met the inclusion criteria were randomly divided into Qianzhisan group and tiapride group with 30 cases in each group. Qiangzhi group took Qianzhisan decoction and Tiapride group orally took tiapride. The patients were followed up for 24 weeks. The types, frequency, intensity, complexity, adverse reaction, safety and long term effect of the two groups were observed before and after treatment, and the types, frequency, intensity, complexity, adverse reactions, safety and long-term efficacy of the two groups were observed. In the experiment, 40 Sprague-Dawley rats were randomly divided into control group, model group, tiapride group and Qiangzhi powder group, with 10 rats in each group. The model of TS rats was established by intraperitoneal injection of IDPN 300 mg / kg / d for 7 days. Qiangzhi San group was treated with 5g/kg, thiapride group was given thiapride according to 25mg/kg dose, and the other two groups were given the same dose of normal saline at the same time. Continuous administration for 4 weeks. The changes of body weight and motor behavior were observed and the content of DANNE in brain tissue was measured. The result is 1: 1. Clinical part: Qiangzhi San was superior to tiapride p0.05 in improving total twitch, movement twitch, twitch frequency, twitch intensity and interference degree of life. In improving phonation twitching, twitch type and complexity, Qianzhi San has the same curative effect as thiapride. In the aspect of improvement of TCM clinical symptoms, Qiangzhi San is obviously superior to tiapride p0.01. 2. Experimental part: the content of DAN in brain tissue of Qiangzhi San group was significantly lower than that of tiapride group. Conclusion: Qiangzhi Powder is safe and effective in the treatment of multiple tic syndrome (deficiency of renal information). Reducing the content of DANe in rat brain may be one of the mechanisms of Qiangzhi Powder in treating tic.
【学位授予单位】：山东中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R249;R277.7

【参考文献】